CAREFUSION 8K Regulation FD Disclosure | SEC 4 Feb 11

Exhibit 99.2

SUPPLEMENTAL FINANCIAL INFORMATION

The following tables present unaudited pro forma quarterly financial data for CareFusion Corporation (the “Company”) for the quarters ended September 30, 2010 and December 31, 2010, and for the six-months ended December 31, 2010. In addition, the following tables present unaudited pro forma quarterly financial information for the Company for each of the quarters in the fiscal year ended June 30, 2010 and for the fiscal year ended June 30, 2010. As set forth in the Form 8-K of which this Exhibit 99.2 forms a part, on February 3, 2011, the Company issued a news release in which the Company announced that it had entered into a definitive agreement with Medline Industries, Inc., for the sale of the Company’s International Surgical Products distribution business. The operations of the International Surgical Products business did not meet the criteria for reclassification as discontinued operations for the quarter ended December 31, 2010, and as a result, this business will be reclassified as discontinued operations beginning in the quarter ending March 31, 2011. The Company is voluntarily providing the unaudited pro forma financial data included in the following tables to reflect the reclassification of this business as if it were discontinued operations for all periods presented so investors can more easily understand the impact on the Company’s financial statements beginning with the quarter ending March 31, 2011.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended September 30, 2010
(in millions, except per share amounts)	GAAP As Reported			Pro Forma Adjustments ¹			Pro Forma Statement of Income			Nonrecurring Items²			Adjusted Pro Forma ³
Revenue	$	908		$	(97	)	$	811		$	—		$	811
Cost of Products Sold		468			(70	)		398			—			398

Gross Margin		440			(27	)		413			—			413

Selling, General and Administrative Expenses		295			(25	)		270			(15	)		255
Research and Development Expenses		40			—			40			—			40
Restructuring and Acquisition Integration Charges		23			—			23			(23	)		—

Operating Income		82			(2	)		80			38			118

Interest Expense and Other, Net		24			—			24			—			24

Income Before Income Tax		58			(2	)		56			38			94
Provision for Income Tax		20			(1	)		19			11			30


Net Income	$	38		$	(1	)	$	37		$	27		$	64


Per Share Amounts:⁴
Basic Earnings per Common Share	$	0.17		$	(0.01	)	$	0.17		$	0.12		$	0.29
Diluted Earnings per Common Share	$	0.17		$	(0.01	)	$	0.16		$	0.12		$	0.29

Weighted-Average Number of Common Shares Outstanding:
Basic		222.1			222.1			222.1			222.1			222.1
Diluted		223.9			223.9			223.9			223.9			223.9

Effective Tax Rate		33.9	%		27.0	%		34.2	%		28.2	%		31.7	%

Reflects the impact of the planned divestiture of the International Surgical Products (ISP) business which will be presented as discontinued operations starting in the quarter ending March 31, 2011. These amounts do not consider an allocation of general corporate overhead costs not specifically related to the ISP business and therefore, selling, general and administrative expenses do not reflect any potential reductions in corporate costs in response to this change in the Company subsequent to the divestiture.

²	Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁴	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended December 31, 2010
(in millions, except per share amounts)	GAAP As Reported			Pro Forma Adjustments ¹			Pro Forma Statement of Income			Nonrecurring Items²			Adjusted Pro Forma ³
Revenue	$	1,002		$	(116	)	$	886		$	—		$	886
Cost of Products Sold		527			(86	)		441			—			441

Gross Margin		475			(30	)		445			—			445

Selling, General and Administrative Expenses		295			(27	)		268			(9	)		259
Research and Development Expenses		36			—			36			—			36
Restructuring and Acquisition Integration Charges		18			—			18			(18	)		—

Operating Income		126			(3	)		123			27			150

Interest Expense and Other, Net		21			—			21			—			21

Income Before Income Tax		105			(3	)		102			27			129
Provision for Income Tax		29			—			29			6			35


Net Income	$	76		$	(3	)	$	73		$	21		$	94


Per Share Amounts:⁴
Basic Earnings per Common Share	$	0.34		$	(0.01	)	$	0.33		$	0.09		$	0.42
Diluted Earnings per Common Share	$	0.34		$	(0.01	)	$	0.33		$	0.09		$	0.42

Weighted-Average Number of Common Shares Outstanding:
Basic		222.8			222.8			222.8			222.8			222.8
Diluted		224.5			224.5			224.5			224.5			224.5

Effective Tax Rate		27.9	%		15.9	%		28.2	%		21.5	%		26.8	%

²	Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁴	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Six Months Ended December 31, 2010
(in millions, except per share amounts)	GAAP As Reported			Pro Forma Adjustments ¹			Pro Forma Statement of Income			Nonrecurring Items²			Adjusted Pro Forma ³
Revenue	$	1,910		$	(213	)	$	1,697		$	—		$	1,697
Cost of Products Sold		995			(156	)		839			—			839

Gross Margin		915			(57	)		858			—			858

Selling, General and Administrative Expenses		590			(52	)		538			(24	)		514
Research and Development Expenses		76			—			76			—			76
Restructuring and Acquisition Integration Charges		41			—			41			(41	)		—

Operating Income		208			(5	)		203			65			268

Interest Expense and Other, Net		45			—			45			—			45

Income Before Income Tax		163			(5	)		158			65			223
Provision for Income Tax		49			(1	)		48			17			65


Net Income	$	114		$	(4	)	$	110		$	48		$	158


Per Share Amounts:⁴
Basic Earnings per Common Share	$	0.51		$	(0.02	)	$	0.50		$	0.22		$	0.71
Diluted Earnings per Common Share	$	0.51		$	(0.02	)	$	0.49		$	0.22		$	0.71

Weighted-Average Number of Common Shares Outstanding:
Basic		222.4			222.4			222.4			222.4			222.4
Diluted		224.2			224.2			224.2			224.2			224.2

Effective Tax Rate		30.0	%		21.1	%		30.3	%		25.5	%		28.9	%

²	Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring tax items. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁴	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended September 30, 2009
(in millions, except per share amounts)	GAAP As Reported			Discontinued Operations¹			Pro Forma Adjustments ²			Pro Forma Statement of Income			Nonrecurring Items³			Adjusted Pro Forma ⁴
Revenue	$	923		$	—		$	(110	)	$	813		$	—		$	813
Cost of Products Sold		472			—			(75	)		397			—			397

Gross Margin		451			—			(35	)		416			—			416

Selling, General and Administrative Expenses		297			—			(28	)		269			(13	)		256
Research and Development Expenses		36			—			—			36			—			36
Restructuring and Acquisition Integration Charges		1			—			—			1			(1	)		—

Operating Income		117			—			(7	)		110			14			124

Interest Expense and Other, Net		42			—			—			42			(22	)		20

Income Before Income Tax		75			—			(7	)		68			36			104
Provision for Income Tax		20			—			(1	)		19			6			25

Income from Continuing Operations		55			—			(6	)		49			30			79
Income from Discontinued Operations, Net of Tax		26			(26	)		—			—			—			—


Net Income	$	81		$	(26	)	$	(6	)	$	49		$	30		$	79


Per Share Amounts:⁵
Basic Earnings per Common Share	$	0.37		$	(0.12	)	$	(0.03	)	$	0.22		$	0.14		$	0.36
Diluted Earnings per Common Share	$	0.37		$	(0.12	)	$	(0.03	)	$	0.22		$	0.14		$	0.36

Weighted-Average Number of Common Shares Outstanding:
Basic		220.6			220.6			220.6			220.6			220.6			220.6
Diluted		221.2			221.2			221.2			221.2			221.2			221.2

Effective Tax Rate		27.0	%		n/a			11.3	%		28.4	%		16.5	%		24.3	%

Reflects the impact of (a) removing certain businesses that manufacture and sell surgical and exam gloves, surgical drapes and apparel and fluid management products in the U.S. market that were previously part of the Clinical and Medical Products segment of Cardinal Health and were retained by Cardinal Health upon the spinoff, and (b) the divestiture of the Company’s audiology business.

Reflects nonrecurring charges primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, and nonrecurring charges related to the bridge loan entered into in connection with the spinoff. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

⁴	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁵	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended December 31, 2009
(in millions, except per share amounts)	GAAP As Reported			Discontinued Operations¹		Pro Forma Adjustments ²			Pro Forma Statement of Income			Nonrecurring Items³			Adjusted Pro Forma ⁴
Revenue	$	1,019		$	—	$	(127	)	$	892		$	—		$	892
Cost of Products Sold		541			—		(98	)		443			—			443

Gross Margin		478			—		(29	)		449			—			449

Selling, General and Administrative Expenses		305			—		(29	)		276			(12	)		264
Research and Development Expenses		37			—		—			37			—			37
Restructuring and Acquisition Integration Charges		9			—		—			9			(9	)		—

Operating Income		127			—		—			127			21			148

Interest Expense and Other, Net		24			—		—			24			—			24

Income Before Income Tax		103			—		—			103			21			124
Provision for Income Tax		30			—		—			30			7			37

Income from Continuing Operations		73			—		—			73			14			87
Loss from Discontinued Operations, Net of Tax		(3	)		3		—			—			—			—


Net Income	$	70		$	3	$	—		$	73		$	14		$	87


Per Share Amounts:⁵
Basic Earnings per Common Share	$	0.32		$	0.01	$	—		$	0.33		$	0.06		$	0.39
Diluted Earnings per Common Share	$	0.32		$	0.01	$	—		$	0.32		$	0.06		$	0.39

Weighted-Average Number of Common Shares Outstanding:
Basic		220.8			220.8		220.8			220.8			220.8			220.8
Diluted		222.2			222.2		222.2			222.2			222.2			222.2

Effective Tax Rate		29.4	%		n/a		1.4	%		29.6	%		33.6	%		30.2	%

¹	Reflects the impact of the divestiture of the Company’s audiology business.

Reflects nonrecurring charges related to the spinoff, nonrecurring charges related to the bridge loan entered into in connection with the spinoff, nonrecurring restructuring and acquisition integration charges and nonrecurring tax items. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

⁴	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁵	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended March 31, 2010
(in millions, except per share amounts)	GAAP As Reported			Pro Forma Adjustments ¹			Pro Forma Statement of Income			Nonrecurring Items²			Adjusted Pro Forma ³
Revenue	$	952		$	(115	)	$	837		$	—		$	837
Cost of Products Sold		500			(77	)		423			—			423

Gross Margin		452			(38	)		414			—			414

Selling, General and Administrative Expenses		316			(31	)		285			(17	)		268
Research and Development Expenses		42			—			42			—			42
Restructuring and Acquisition Integration Charges		1			—			1			(1	)		—

Operating Income		93			(7	)		86			18			104

Interest Expense and Other, Net		29			—			29			—			29

Income Before Income Tax		64			(7	)		57			18			75
Provision for Income Tax		73			(1	)		72			(48	)		24


Net Income (Loss)	$	(9	)	$	(6	)	$	(15	)	$	66		$	51


Per Share Amounts:⁴
Basic Earnings (Loss) per Common Share	$	(0.04	)	$	(0.03	)	$	(0.07	)	$	0.30		$	0.23
Diluted Earnings (Loss) per Common Share	$	(0.04	)	$	(0.03	)	$	(0.07	)	$	0.30		$	0.23

Weighted-Average Number of Common Shares Outstanding:
Basic		221.6			221.6			221.6			221.6			221.6
Diluted⁵		221.6			221.6			221.6			221.6			221.6

Effective Tax Rate		114.1	%		15.5	%		125.5	%		(258.3	%)		31.8	%

Reflects nonrecurring charges related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions, and nonrecurring tax items associated with the other non-tax adjustments. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁴	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

⁵	Dilutive shares outstanding equal basic shares outstanding for the quarter ended March 31, 2010 as the impact would be anti-dilutive.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended June 30, 2010
(in millions, except per share amounts)	GAAP As Reported			Pro Forma Adjustments ¹			Pro Forma Statement of Income			Nonrecurring Items²			Adjusted Pro Forma ³
Revenue	$	1,035		$	(105	)	$	930		$	—		$	930
Cost of Products Sold		550			(73	)		477			—			477

Gross Margin		485			(32	)		453			—			453

Selling, General and Administrative Expenses		310			(23	)		287			(17	)		270
Research and Development Expenses		44			—			44			—			44
Restructuring and Acquisition Integration Charges		8			—			8			(8	)		—
Gain on the Sale of Assets		(12	)		—			(12	)		12			—

Operating Income		135			(9	)		126			13			139

Interest Expense and Other, Net		20			—			20			—			20

Income Before Income Tax		115			(9	)		106			13			119
Provision for Income Tax		63			(3	)		60			(20	)		40


Net Income	$	52		$	(6	)	$	46		$	33		$	79


Per Share Amounts:⁴
Basic Earnings per Common Share	$	0.24		$	(0.03	)	$	0.21		$	0.15		$	0.36
Diluted Earnings per Common Share	$	0.23		$	(0.03	)	$	0.21		$	0.15		$	0.35

Weighted-Average Number of Common Shares Outstanding:
Basic		221.8			221.8			221.8			221.8			221.8
Diluted		224.0			224.0			224.0			224.0			224.0

Effective Tax Rate		54.5	%		34.8	%		56.2	%		(164.7	%)		33.1	%

Reflects nonrecurring charges, primarily related to the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on the sale of assets and nonrecurring tax items. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁴	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

PRO FORMA ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Fiscal Year Ended June 30, 2010
(in millions, except per share amounts)	GAAP As Reported			Discontinued Operations¹			Pro Forma Adjustments ²			Pro Forma Statement of Income			Nonrecurring Items³			Adjusted Pro Forma ⁴
Revenue	$	3,929		$	—		$	(457	)	$	3,472		$	—		$	3,472
Cost of Products Sold		2,063			—			(323	)		1,740			—			1,740

Gross Margin		1,866			—			(134	)		1,732			—			1,732

Selling, General and Administrative Expenses		1,228			—			(111	)		1,117			(59	)		1,058
Research and Development Expenses		159			—			—			159			—			159
Restructuring and Acquisition Integration Charges		19						—			19			(19	)		—
Gain on the Sale of Assets		(12	)		—			—			(12	)		12			—

Operating Income		472			—			(23	)		449			66			515

Interest Expense and Other, Net		115			—			—			115			(22	)		93

Income Before Income Tax		357			—			(23	)		334			88			422
Provision for Income Tax		186			—			(5	)		181			(55	)		126

Income from Continuing Operations		171			—			(18	)		153			143			296
Income from Discontinued Operations, Net of Tax		23			(23	)		—			—			—			—


Net Income	$	194		$	(23	)	$	(18	)	$	153		$	143		$	296


Per Share Amounts:⁵
Basic Earnings per Common Share	$	0.88		$	(0.10	)	$	(0.08	)	$	0.69		$	0.65		$	1.34
Diluted Earnings per Common Share	$	0.87		$	(0.10	)	$	(0.08	)	$	0.69		$	0.64		$	1.33

Weighted-Average Number of Common Shares Outstanding:
Basic		221.5			221.5			221.5			221.5			221.5			221.5
Diluted		223.0			223.0			223.0			223.0			223.0			223.0

Effective Tax Rate		52.1	%		n/a			21.5	%		54.2	%		(63.1	%)		29.8	%

Reflects nonrecurring charges primarily related to the spinoff, nonrecurring charges related to the bridge loan entered into in connection with the spinoff, nonrecurring restructuring and acquisition integration charges, nonrecurring gain on sale of assets, nonrecurring charges related to a tax reserve adjustment ($58 million) for uncertain tax positions recorded in the quarter ended March 31, 2010, and nonrecurring tax items associated with the other non-tax adjustments. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

⁴	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁵	Earnings per share calculations are performed separately for each adjustment presented. Therefore, the sum of the per share adjustments from the table above may not equal the adjusted per share totals presented.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended September 30, 2010
(in millions)	GAAP As Reported		Pro Forma Adjustments¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma ³
Critical Care Technologies
Revenue	$	617	$	—		$	617	$	—	$	617
Operating Income		71		—			71		29		100

Medical Technologies and Services
Revenue	$	291	$	(97	)	$	194	$	—	$	194
Operating Income		11		(2	)		9		9		18

	Quarter Ended December 31, 2010
(in millions)	GAAP As Reported		Pro Forma Adjustments¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma ³
Critical Care Technologies
Revenue	$	684	$	—		$	684	$	—	$	684
Operating Income		110		—			110		18		128

Medical Technologies and Services
Revenue	$	318	$	(116	)	$	202	$	—	$	202
Operating Income		16		(3	)		13		9		22

	Six Months Ended December 31, 2010
(in millions)	GAAP As Reported		Pro Forma Adjustments ¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma³
Critical Care Technologies
Revenue	$	1,301	$	—		$	1,301	$	—	$	1,301
Operating Income		181		—			181		47		228

Medical Technologies and Services
Revenue	$	609	$	(213	)	$	396	$	—	$	396
Operating Income		27		(5	)		22		18		40

¹	Reflects the impact of the planned divestiture of the International Surgical Products (ISP) business which will be presented as discontinued operations starting in the quarter ending March 31, 2011.

²	Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

CAREFUSION CORPORATION

ADJUSTED FINANCIAL INFORMATION

(UNAUDITED)


	Quarter Ended September 30, 2009
(in millions)	GAAP As Reported		Pro Forma Adjustments¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma ³
Critical Care Technologies
Revenue	$	617	$	—		$	617	$	—	$	617
Operating Income		101		—			101		11		112

Medical Technologies and Services
Revenue	$	306	$	(110	)	$	196	$	—	$	196
Operating Income		16		(7	)		9		4		13

	Quarter Ended December 31, 2009
(in millions)	GAAP As Reported		Pro Forma Adjustments¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma³
Critical Care Technologies
Revenue	$	682	$	—		$	682	$	—	$	682
Operating Income		111		—			111		15		126

Medical Technologies and Services
Revenue	$	337	$	(127	)	$	210	$	—	$	210
Operating Income		16		—			16		6		22

	Quarter Ended March 31, 2010
(in millions)	GAAP As Reported		Pro Forma Adjustments ¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma³
Critical Care Technologies
Revenue	$	629	$	—		$	629	$	—	$	629
Operating Income		77		—			77		13		90

Medical Technologies and Services
Revenue	$	323	$	(115	)	$	208	$	—	$	208
Operating Income		16		(7	)		9		5		14

	Quarter Ended June 30, 2010
(in millions)	GAAP As Reported		Pro Forma Adjustments ¹			Pro Forma Results		Nonrecurring Items²		Adjusted Pro Forma³
Critical Care Technologies
Revenue	$	716	$	—		$	716	$	—	$	716
Operating Income⁴		106		—			106		17		123

Medical Technologies and Services
Revenue	$	319	$	(105	)	$	214	$	—	$	214
Operating Income⁴		17		(9	)		8		8		16

	Year Ended June 30, 2010
(in millions)	GAAP As Reported		Pro Forma Adjustments ¹			Pro Forma Results		Nonrecurring Items ²		Adjusted Pro Forma³
Critical Care Technologies
Revenue	$	2,644	$	—		$	2,644	$	—	$	2,644
Operating Income⁴		395		—			395		55		450

Medical Technologies and Services
Revenue	$	1,285	$	(457	)	$	828	$	—	$	828
Operating Income⁴		65		(23	)		42		23		65

¹	Reflects the impact of the planned divestiture of the International Surgical Products (ISP) business which will be presented as discontinued operations starting in the quarter ending March 31, 2011.

²	Reflects nonrecurring charges primarily related to the spinoff and nonrecurring restructuring and acquisition integration charges. Certain nonrecurring costs previously reported were applicable to ISP and therefore were reclassified to be reflected as part of that business.

³	Adjusted pro forma financial information reflects GAAP results adjusted on a non-GAAP basis to exclude the ISP business and nonrecurring items noted.

⁴	Not included in segment operating income for the quarter and year ended June 30, 2010 is a gain on the sale of assets associated with the May 2010 divestiture of our Research Services business.

CAREFUSION Inactive 8-KRegulation FD Disclosure